In the complex realm of patent law, the case of United Therapeutics Corporation v. Liquidia Technologies, Inc. offers some critical insights. This case, an appeal and cross-appeal originating from a District of Delaware decision, touches on several key issues relating to patent infringement and validity.
The case centers around the status of several different claims across two U.S. patents – 10,716,793 (“the ’793 patent”) and 9,593,066 (“the ’066 patent”). In the original district court decision, the court found claims 1, 4, and 6-8 of the ’793 patent to be not invalid and infringed, while claims 1-3 of the ’066 patent were declared invalid as anticipated despite being otherwise infringed. Interestingly, claims 6 and 9 of the ’066 patent were also judged as invalid as anticipated and claims 6, 8, and 9 of the ’066 patent were deemed not to be infringed.
A significant aspect to note in this case is the district court’s decision to invalidate claims due to inherent anticipation. Inherent anticipation is a concept in patent law which suggests that if all elements of a claim are found within a single prior art reference, the claim is inherently anticipated and therefore not patentable. The Federal Circuit upheld this aspect of the district court’s decision on appeal, leaving us with a notable precedent.
For in-house counsel and legal professionals within the corporate world, this case serves as a reminder of the complexities inherent in patent law, particularly as it relates to claim validity and patent infringements. It further highlights the importance of thoroughly grounding any patent applications in a strong understanding of the current legal landscape and solid anticipation of potential challenges. As the dynamics of patent law continue to evolve, such cases underscore the ongoing demand for meticulous attention to detail, rigorous analysis, and savvy legal strategies.